Following on from information provided to NICE by the company in September 2019, the appraisal of Lymphoma (diffuse large B-cell, activated, untreated) - lenalidomide (with R-CHOP) [ID1611] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1611 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2019, the appraisal of Lymphoma (diffuse large B-cell, activated, untreated) - lenalidomide (with R-CHOP) [ID1611] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 September 2019 | Suspended. Referred 18 March 2019 |
| 19 September 2019 | The company have informed NICE that the phase III ROBUST trial evaluating REVLIMID plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy (R2-CHOP) in patients with previously untreated activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL) did not meet the primary endpoint of demonstrating superiority in progression-free survival (PFS) compared to placebo plus R-CHOP. As a result the company will not be filing for a Marketing Authorisation Application to the European Medicines Authority in this indication at this time. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 08 May 2019 | In progress. Referred 18 March 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual